At Pfizer, we strive to set the standard for quality, safety and value in our health care products. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. As one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.
The Menarini Group is the leading Italian pharmaceutical company in the world, a guarantee of internationally recognized quality. With 16 Manufacturing sites and 7 R&D Centers, the Menarini Group is present in more than 100 countries worldwide, a guarantee of internationally recognized quality. The achieved results are proof of an efficient strategy based on Research, Innovation and Internationalization, along with the ability to recognize and meet the needs of physicians and patients alike. Recently, the Menarini Group has expanded its portfolio by adding a high-value antibiotics platform to its therapeutic armamentarium in order to pursue its “infection in focus” mission: fight life-threatening bacterial infections which represent a rising global concern.
Accelerate Diagnostics is an in-vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and Healthcare Associated Infections. The company’s fully automated ID/AST system, helps you to move your patients from empiric to optimal therapy faster using MIC results from the Accelerate PhenoTM system. Powered by Morphokinetic Cellular Analysis (MCA), the Accelerate PhenoTM system is the first to track phenotypic features such as the size, shape, and division rate
of individual live cells growing into micro-colonies while being challenged by antimicrobials.
The Accelerate PhenoTestTM BC Kit makes earlier optimal therapy possible by providing answers, directly from positive blood cultures, that drive treatment decisions 1-2 days faster than current methods allow today. Earlier optimal therapy can lead to reduced cost of patient care, fewer adverse incidents, lower rate of resistance, and better clinical outcomes.
Correvio licenses XYDALBATM (dalbavancin hydrochloride), a second generation, semi- synthetic lipoglycopeptide approved in the EU for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults for select European and Middle Eastern nations from Allergan; and TREVYENT®, a development stage drug device combination that is under development for Pulmonary Arterial Hypertension (PAH) for select markets in Europe and the Middle East from SteadyMed Therapeutics. Recently, Correvio also licensed ZEVTERA®/MABELIO® (ceftobiprole medocaril), a semi-synthetic, pro-drug form of a cephalosporin antibiotic for the treatment of community acquired pneumonia (CAP) and hospital acquired pneumonia (HAP) excluding ventilator acquired pneumonia (VAP) in adults for select European markets and Israel from Basilea Pharmaceutica.
Correvio also has two marketed, in-hospital, cardiology products: BRINAVESS® (vernakalant HCl, IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT® (tirofiban
HCl), a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome (ACS). Correvio commercializes BRINAVESS® and AGGRASTAT® directly in European markets, and through a network of partners in ex-US global markets . Correvio also commercializes ESMOCARD® and ESMOCARD LYO® (esmolol hydrochloride), a short-acting beta-blocker used to control rapid heart rate in a number
of cardiovascular indications, including supraventricular tachycardia (SVT), on behalf of its partner AOP Orphan Pharma in select European markets.
Shionogi & Co. Ltd. was founded nearly 140 years ago in Osaka, Japan. Shionogi Europe is a newer venture, launched in 2012 as part of a new global era for the company. Our commitment is to ensure that the real-life challenges patients face are the primary driver behind our R&D.
Our research-led organisation is defined by a distinct openness and close partnership approach to creating anti-infectives, vaccines and other medicines. We have an impressive legacy of fostering long-term scientific and industry partnerships built on a mutual ambition to develop innovative medicines that address unmet medical needs.